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Structure–function analysisSuccinyl-CoA:3-ketoacid CoA transferase (SCOT) deﬁciency is an inborn error of ketone body metabolism and
causes episodic ketoacidosis. We report clinical and molecular analyses of 5 patients with SCOT deﬁciency.
Patients GS07, GS13, and GS14 are homozygotes of S405P, L327P, and R468C, respectively. GS17 and GS18 are
compound heterozygotes for S226N and A215V, and V404F and E273X, respectively. These mutations have
not been reported previously. Missensemutations were further characterized by transient expression analysis
of mutant cDNAs. Among 6 missense mutations, mutants L327P, R468C, and A215V retained some residual
activities and their mutant proteins were detected in immunoblot analysis following expression at 37 °C. They
were more stable at 30 °C than 37 °C, indicating their temperature sensitive character. The R468C mutant is a
distinct temperature sensitive mutant which retained 12% and 51% of wild-type residual activities at 37 and
30 °C, respectively. The S226N mutant protein was detected but retained no residual activity. Effects of
missense mutations were predicted from the tertiary structure of the SCOT molecule. Main effects of these
mutations were destabilization of SCOT molecules, and some of them also affected catalytic activity. Among 5
patients, GS07 and GS18 had null mutations in both alleles and the other three patients retained some residual
SCOT activities. All 5 developed a ﬁrst severe ketoacidotic crisis with blood gas pH b7.1, and experienced
multiple ketoacidotic decompensations (two of them had seven such episodes). In general, the outcome was
good even following multiple ketoacidotic events. Permanent ketosis or ketonuria is considered a
pathognomonic feature of SCOT deﬁciency. However, this condition depends not only on residual activity
but also on environmental factors.ces Division, United Graduate
ces; Department of Pediatrics,
ido, Gifu, Gifu 501-1194, Japan.
l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Ketone bodies, producedmainly in the liver, are an important source
of energy for extrahepatic tissues [1]. Succinyl-CoA: 3-ketoacid CoA
transferase (SCOT; EC 2.8.3.5, gene symbol OXCT1) is a mitochondrial
homodimer essential for ketone body utilization. SCOT catalyzes
acetoacetate activation to acetoacetyl-CoA in mitochondria. Thehuman OXCT1 gene is mapped to 5p13 and consists of 17 exons [2,3].
Human SCOT cDNA encodes a precursor subunit of 520 amino acids.
Patients with SCOT deﬁciency (OMIM 245050) experience episodic
ketoacidosis and are usually asymptomatic between episodes. Fewer
than 30 affected individuals are known [2–22]. Urinary organic acid
analysis and acylcarnitine analysis show non-speciﬁc proﬁles in this
disorder.Hence, invitromethodsof diagnosis, suchasenzymeassay and
mutation analysis, are essential for the deﬁnite diagnosis. Permanent
ketosis or ketonuria is a pathognomonic feature of this disorder but is
not always present [17,20,22].We previously identiﬁed 11mutations of
the OXCT1 gene [6,8–14] in 12 SCOT-deﬁcient families.
Recently, the human SCOT tertiary structure has become available
(PDB entry 3DLX). This has enabled us to evaluate effects of missense
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SCOT structure [20].
We herein describe 5 SCOT-deﬁcient patients and characterize
their mutations by transient expression analysis of mutant cDNAs and
discuss the mutation sites on the tertiary structure of human SCOT.
2. Patients, materials and methods
2.1. Patients
GS07: Clinical ﬁndings of GS07 have been reported previously [11].
Brieﬂy, he presented with two episodes of ketoacidosis during
infections at 17 and 25 months of age. He was followed until age
6 years without any further episodes.
GS13: Some aspects of GS13 have already been published [14].
Although parents are not known to be related, the family originates
from a small socially isolated area, making consanguinity not unlikely.
After an initial severe crisis at age 6 months, the girl had three
additional, but milder crises during infancy. After 6 h of fasting during
a test performed after the ﬁrst crisis, her blood pH was 7.42, HCO3
12.5 mmol/L and BE −9.1 mmol/L, with high serum ketones
3.55 mmol/L and low FFA of 0.29 mmol/L. At the age of 12.5 years
she is now doing well, attending a regular school. She usually takes
her last meal at about 10 p.m. and takes ﬁrst morning meal in school
at about 9 to 10 a.m. without any signs or symptoms. Acid-base
balance was checked three times at about 8 a.m. and was always
normal.
GS14: This female patient of 21 years of age was born to
consanguineous parents in October 1988. She had many hospitaliza-
tions in the pediatric ward for episodes of hypoglycemia. Her ﬁrst
hospitalization was at 19 months for seizures and coma. On physical
exam she had deep respiration. Her blood glucose was 1.3 mmol/L, She
had severe metabolic acidosis with pH 6.93, HCO3 6 mmol/L and
ketonuria 3+. She had six similar episodes of hypoglycemia with
ketoacidosis without seizures, usually after episodes of infections. Her
neuro-developmental status was normal. She had persistent ketonuria
between episodes of decompensation.
GS17: She is a Caucasian girl born to non-consanguineous parents
at full-term with a birth weight of 2230 g. She had low blood glucose
levels of 1.6 mmol/L on the ﬁrst day of life and received intravenous
glucose for 1–2 days. She was discharged on day 5 of life. She was well
until 3 years of age when she developed tachypnea and lethargy
following gastroenteritis. Her blood pHwas 6.99with BE−25 mmol/L
and her blood glucose was 7.5 mmol/L. Urine analysis showed
massive ketones. She was intubated and admitted to the intensive
care unit. She responded to intravenous glucose and bicarbonate and
was discharged after 7 days. Six months later she was readmitted to a
local hospital with mild lethargy, tachypnea and ketoacidosis which
developed during a febrile upper respiratory infection. The patient's
mother reported that the patient has had trace to moderate ketonuria,
even when she was in good health. SCOT deﬁciency was conﬁrmed by
an enzyme assay using ﬁbroblasts. The patient has not had any more
episodes of ketoacidosis for 6 years. She is doing well and receives a
mildly protein-restricted diet (2.0 g/kg/day), avoids prolonged fasting
and adheres to “sick day” precautions such as increasing calories from
carbohydrates in her diet and intravenous glucose as needed.
GS18: The male patient, ﬁrst child of healthy non-consanguineous
parents from Vietnam, was born at 39 weeks with a birth weight of
3390 g. After a normal clinical presentation during the ﬁrst days of life
he was readmitted to hospital at the age of 3 days with polypnea.
Biochemically he presented with severe metabolic acidosis (pH 7.08,
pCO2 25 mmHg, BE−22.6 mmol/l) and pronounced ketonuria. Beside
ketones, metabolic screening revealed unremarkable urinary organic
acids. With intravenous ﬂuid with sodium bicarbonate the patient
recovered within hours. During the ﬁrst year of life the patient was
hospitalized three times because of episodes of severe ketoacidosis(minimal pH 6.98, pCO2 15 mmHg, BE −28 mmol/l). At the age of
1 year, SCOT deﬁciency was conﬁrmed by an enzyme assay using his
lymphocytes and platelets. He was on treatment that consisted of
avoidance of prolonged fasting and moderate protein restriction
(1.5 g/kg/d). Subsequently the patient has had three more severe
episodes of ketoacidosis in the course of intercurrent diseases.
Otherwise, he has permanent mild ketonuria. At his present age of
10 years psychomotor and physical development are normal.
Table 1 summarizes the clinical presentations and laboratory data of
these 5 SCOT-deﬁcient patients. This study has been approved by The
Ethical Committee of Graduate School of Medicine, Gifu University.
2.2. Enzyme assay and immunoblot analysis
Assays for acetoacetyl-CoA thiolase and for SCOTwere performed as
described [7,23], using acetoacetyl-CoA as a substrate andmeasuring its
disappearance spectrophotometrically.
2.3. Mutation analysis
Total RNA was puriﬁed from peripheral blood mononuclear cells
with an ISOGEN kit (Nippon Gene, Tokyo, Japan). RT-PCR was as
described [2]. Mutations were detected by amplifying cDNA spanning
the full-length coding sequence, and sequencing more than 5 clones.
Genomic DNA was puriﬁed with a Sepa Gene kit (Sanko Junyaku,
Tokyo, Japan). Mutation analysis at the genomic level was done by
PCR for each exon and its intron boundaries (at least 20 bases from the
exon/intron boundaries for both directions) followed by direct
sequencing [3].
2.4. Construction of eukaryote transient expression vectors
Wild-type full-length SCOT cDNAs [3] were subcloned into the
pTZ18U and pCAGGS eukaryote expression vectors [24] and desig-
nated the pTscotWild-type and pCAGGSscotWild-type, respectively.
Mutations were introduced into the pTscotWild-type using a
QuikChange Site-Directed Mutagenesis kit (Stratagene, La Jolla CA),
conﬁrmed by sequencing, and then transferred into pCAGGS.
2.5. Transient expression analysis
Wild-type and mutant SCOT expression vectors (4 μg) were ﬁrst
transfected using Lipofectamine 2000 (GIBCO BRL Invitrogen Inc.,
Carlsbad, CA) in ~105 SV40-transformed SCOT-deﬁcient ﬁbroblasts of
GS01[2]. One microgram of the cytosolic acetoacetyl-CoA thiolase
(CT)-expressing vector, pCAGGSct [25], was cotransfected to monitor
transfection efﬁciency. Transfection was done at 37 °C for 24 h was
followed by a further 48-h incubation at 37 or 30 °C. The cells were
harvested and stored at −80 °C until SCOT and CT activities were
assayed. Immunoblot was done using a mixture of anti-[human SCOT]
antibody and anti-[human CT] antibody as the ﬁrst antibody [26]. The
quantity of mutant protein was estimated densitometrically, and was
compared to the signal intensities of serially diluted samples of the
wild-type SCOT protein.
2.6. Tertiary structural model of human SCOT
To analyze the putative structural implications of the SCOT
mutations, the recently determined crystal structure from the
Structural Genomics Consortium (PDB entry 3DLX) of human SCOT
was taken as a starting point. Prior to the analysis, the structure was
subjected to further reﬁnement in PHENIX [27] and COOT [28],
including the addition of missing side chains and rebuilding of the
solvent network. The ﬁgures describing the structural details were
prepared with PyMOL.
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3.1. Enzyme assay
Enzyme assay data for 4 patients are shown in Table 2. All four
patients’ ﬁbroblasts presented with decreased SCOT activity, whereas
they had a potassium-ion activated acetoacetyl-CoA thiolase activity
which was a speciﬁc character of mitochondrial acetoacetyl-CoA
thiolase (T2). In immunoblot analysis, SCOT protein was scarcely
detected in these patients’ cells, whereas T2 protein was clearly
detected (data not shown). Lymphocytes and platelets from GS18 had
no apparent SCOT activity (data not shown). These results conﬁrmed
the diagnosis of SCOT deﬁciency in the 5 patients.
3.2. Mutation analysis
Both genomic mutation analysis and cDNA analysis were done in
all the cases except for GS18 of whom RNA was not available. The
results of mutation analyses are shown in Table 1. Three patients with
deﬁnite or possible consanguinity had homozygous mutations
(c.1213TNC (S406P) in GS07; c.980TNC (L327P) in GS13; c.1402CNT
(R468C) in GS14). GS17 is a compound heterozygote of c.644CNT
(A215V) from the father and c.677GNA (S266N) from the mother.
GS18 is also a compound heterozygote of c.817GNT (E273X) from the
father and c.1210GNT (V404F) from the mother. We also detected
three single nucleotide polymorphisms. Among them, c.173CNT
(T58M) (rs75134564) was previously identiﬁed in a Japanese patient
(GS02) and demonstrated not to reduce enzyme activity [13].
3.3. Transient expression analysis of mutant cDNAs
We performed transient expression analysis of wild-type and
mutant cDNAs in SCOT-deﬁcient SV40-transformed ﬁbroblasts.
Following expression of SCOT cDNAs for 48 h at either 37 or 30 °C,
an enzyme assay and immunoblots were performed (Fig. 1). The
transfection of wild-type SCOT cDNA produced high SCOT activity,
whereas that of mock cDNA produced no demonstrable enzyme
activity at any temperature. Among 6 missense mutations, S226N,
V404F, and S405P did not retain residual SCOT activity. The A215V,
L327P and R468C mutants retained detectable residual activities, 3.5,
4.7 and 12% of the wild-type value, respectively, in expression at
37 °C. Their relative residual SCOT activities to wild-type in expression
at 30 °C were 3- to 4-fold higher than those in expression at 37 °C. In
particular, R468Cmutants retained a 51% activity of wild-type value in
the expression at 30 °C. In immunoblot analysis, V404F and S405P
protein was not detected in expression at 30 and 37 °C. S226N protein
was clearly detected in the expression at 30 °C without any detectable
residual activity, indicating that S226N protein was an inactive
protein. The relative amount of the A215V, L327P, and R468C mutant
proteins, as compared to the wild-type, was estimated to be 30%, 30%,
and 50%, respectively, in expression at 30 °C. These proteins were
more stable at 30 °C than at 37 °C. Speciﬁc activities (activity/protein)
of A215V, L327P, and R468Cmutants could be calculated to about 50%,
50%, and 100% that of wild-type, respectively.Table 2
Enzyme assay using ﬁbroblasts.
Acetoacetyl-CoA thiolase SCOT SCOT/+K+
−K+ +K+ +K+/−K+
GS07 5.9 12.9 2.2 1.9 0.2
GS13 4.3 9.1 2.1 0.8 0.1
GS14 3.6 7.3 2.0 1.2 0.2
GS17 7.0 14.9 2.1 1.2 0.1
Controls (n=5) 5.0±0.7 10.8±0.9 2.2±0.3 6.7±2.1 0.6±0.2
Enzyme activity is expressed as nmol/min/mg protein.
Fibroblasts from GS18 were not available.
Fig. 1. Transient expression results for wild-type andmutant SCOT cDNAs. Wild-type and
mutant SCOTexpressionvectors (4 μg)were transfected togetherwith1 μgof the cytosolic
acetoacetyl-CoA thiolase (CT)-expressing vector, pCAGGSct, to SV40-transformed
ﬁbroblasts of GS01 of which the mutation is S283X/S283X. Transient expression was
done 37 and 30 °C. Mock, transfection of 1 μg of pCAGGSct and 4 μg of pCAGGS vectors
without insert. (A) SCOT activities relative to those in wild-type transfection are shown.
The mean values are displayed together with the SD of three independent experiments.
(B) Immunoblots for SCOT and CT are shown. The protein amounts applied are shown
above the lanes. Theﬁrst antibodywasamixtureof ananti-CT (cytosolic thiolase) antibody
and anti-SCOT antibody. The positions of the bands for CT and SCOT are indicated by
arrows.
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A number of mutations have been characterized for SCOT
deﬁciency, and several of them have been structurally analyzed
before [3,20,22], based on homology models of human SCOT, made
with the help of the pig SCOT crystal structure [20]. Fig. 2A shows a
dimer of human SCOT, with presently and previously identiﬁed
mutations highlighted on the SCOT monomer in Fig. 2B. It is
noteworthy that most of the mutations are located around two ‘hot-
spots’ in 3D space; these areas correspond to a small beta sandwich
domain in the N-terminal lobe, and a larger beta sandwich structure
close to the C terminus. Sporadic mutations are also seen closer to the
active site cavity.
The mutation A215V involves the residue A215, which in the wild-
type protein is in the middle of a beta sheet, pointing inwards into the
protein. The terminal carbon atom of A215 is only 3.6 Å away from the
terminal methyl group carbons of L269 in an opposing beta sheet.
Thus, even a small valine residue cannot be incorporated into this
position without structural strain and changes. The position is located
at a small beta sandwich domain involved in SCOT dimer formation.
A215 is, furthermore, in the very close vicinity of the previously
characterized SCOT mutations G219E and V221M [3]. These observa-
tions on the tertiary structure are in accord with the results that themain mutant effect of A215V is the instability of the mutant protein
since the mutant protein amount was 12.5% and 30% relative to wild-
type at 37 and 30 °C, respectively.
S226 is located close to the dimerization interface, although not
being directly involved in it. The side chain is hydrogen-bonded to the
backbone carbonyl of D362 and via a buried water molecule to N345;
N345 is vicinal to the crucial catalytic residue E344 (Fig. 2D). Thus, the
S226N mutation is likely to disturb the structure at least locally, and
could also affect the properties of the catalytic site. As expected from
the view of tertiary structure, the S226Nmutant protein was revealed
to be unstable and non-functional protein was detected in transient
expression analysis.
L327 locates to an alpha helix on the SCOT surface, close to the
active site entrance (Fig. 2D). The side chain of L327 is solvent-
exposed and disordered in the crystal. This helix could form part of the
CoA substrate-binding site, and a proline mutation in the central part
of this helix may both perturb the helical structure and affect the
functional mobility of this region, especially since the neighboring
residue (326) is also a proline. A main mutant effect of L327P is the
instability of themutant protein since themutant protein amountwas
12.5% and 30% relative to wild-type at 37 and 30 °C, respectively.
V404 locates to the C-terminal beta sandwich domain of SCOT
(Fig. 2E). The side chain points inwards, into a tightly packed
hydrophobic core between two beta sheets. There clearly is no room
for a large Phe residue, as there are several short distances from the
side chain of V404 to residues from the opposing beta sheet. S405 is
neighboring V404, at the end of a beta strand, preceding a short tight
beta turn (Fig. 2E). In light of this, the side chain hydroxyl group is
within hydrogen bonding distance from three main-chain NH groups
from residues 407–409. Such an arrangement would be completely
destroyed upon mutation of residue 405 to proline. As expected from
the tertiary structure, these mutant proteins were too unstable to
detect in either the 37 or 30 °C expression.
R468 is an exposed residue, present in the beta sheet opposite to
that harboring V404 and S405. Its side chain is a central residue in a
salt bridge network with E488, R308, E312, K436, and D477 (Fig. 2F).
Mutation of the R468 residue will be detrimental to this large
hydrophilic region on the surface of the C-terminal domain of SCOT.
Since its speciﬁc activity is similar to wild-type, R468C does not affect
catalytic activity; the active site residues are far from this mutation.
Themainmutational effect of R468C is also instability of themolecule.
3.5. Clinical phenotypes and genotypes
We reported herein 5 SCOT-deﬁcient patients and their clinical
andmolecular aspects are summarized in Table 1. They developed the
ﬁrst ketoacidotic episodes from 3 days of age to 3 years of age. The
episodes were associated with very severe metabolic acidosis with
blood pH ranging from 6.90 to 7.08. They all recovered from the ﬁrst
ketoacidotic crises and were well managed after the diagnosis of SCOT
deﬁciency was made. We previously reported clinical and molecular
characters for 12 SCOT-deﬁcient families and now have added to
those 5 more.
Permanent ketosis or persistent ketonuria is pathognomonic feature
of SCOT deﬁciency. We, however, previously showed that SCOT-
deﬁcient patients with “mild” mutations may have no permanent
ketosis. V221M, R268H, or T435N homozygotes and T435N/null
mutation compound heterozygotes did not show permanent ketosis
or permanent ketonuria [3,17,20,22]. V221M, R268H and T435N
mutations retained 10%, 34% and 25%, respectively, relative activity to
wild-type in 37 °C expression using the same expression system. In the
present study, L327P and R468H mutations retained 4.7% and 12%,
respectively, relative activity in 37 °C expression. A L327P homozygote,
GS13, did not have permanent ketonuria but a R468H homozygote;
GS14 did. To our knowledge, patients with null mutations all showed
permanent ketonemia or ketonuria. Hence “mild” mutation with
Fig. 2.Mutation sites on the tertiary structure of SCOT monomer. (A) An overall structure of human SCOT dimmer (PDB entry 3DLX). (B) A monomer of human SCOT. The N and C
termini are labelled. The two clusters of mutations are indicated by ellipsoids. The positions of the mutations identiﬁed in this study are in red, and the ones previously identiﬁed are
shown in yellow. The position of the catalytically active glutamate residue 344 is marked with a blue sphere. (C) The environment of the A215V mutation in the tightly packed
hydrophobic core of the small beta sandwich. The N terminus of the crystal structure is at the bottom front. (D) S226 lies close to the active site, and interacts with N345 via a water-
mediated hydrogen bond (green) and by van der Waals interactions. The catalytic residue is E344. L327 also lies close to the entrance of the catalytic cavity and could be involved in
substrate binding. (E) V404 and S405 are next to each other, V404 being buried at the hydrophobic core of a beta sandwich unit. S405 interacts with the backbone amides of a tight
turn (blue). (F) R468 plays a central role in a salt bridge network linking a beta sheet and a helix.
623T. Fukao et al. / Biochimica et Biophysica Acta 1812 (2011) 619–624residual activity may be a necessary condition but not a sufﬁcient
condition for the absence of permanent ketonemia or ketonuria.
Environmental factors may also affect a clinical phenotype of persistent
ketonuria.
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